Cytosorbents (CTSO) Cost of Revenue (2011 - 2026)

Cytosorbents (CTSO) has 16 years of Cost of Revenue data on file, last reported at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 811.33% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $10.8 million (up 21.3% YoY), and the FY2025 full-year result was $10.6 million, down 1.27% from the prior year.
• Cost of Revenue for Q1 2026 stood at $2.7 million, up from $2.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $4.5 million in Q3 2022 and bottomed at -$9.9 million in Q4 2022.
• The 5-year median for Cost of Revenue is $2.4 million (2025), against an average of $1.8 million.
• The widest annual swing landed in 2022, when Cost of Revenue sank 415.68%; it then soared 811.33% in 2026.
• A 5-year view of Cost of Revenue shows it stood at -$9.9 million in 2022, then surged by 123.8% to $2.3 million in 2023, then gained by 23.42% to $2.9 million in 2024, then decreased by 16.09% to $2.4 million in 2025, then grew by 12.51% to $2.7 million in 2026.
• The last three Cost of Revenue figures came in at $2.7 million (Q1 2026), $2.4 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.

Peer Comparison